Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 9/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.36 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5099589 | 0.82 | OPRD1 (0.35) | GHSRSLC6A2SLC6A4ANPEPRNPEP | |
| SCHEMBL6764546 | 0.79 | LMNA (0.34) | — | |
| SCHEMBL4767101 | 0.79 | CTSD (0.37) | GHSRSLC6A2SLC6A4CTSDSLC6A3 | |
| SCHEMBL7430902 | 0.79 | ALDH1A1 (0.38) | GHSRSLC6A2SLC6A4CTSD | |
| SCHEMBL4766714 | 0.78 | GHSR (0.37) | GHSRSLC6A2SLC6A4CTSDSLC6A3 | |
| SCHEMBL4936544 | 0.78 | GHSR (0.37) | GHSRSLC6A2SLC6A4CTSDSLC6A3 | |
| SCHEMBL6630511 | 0.77 | GRN (0.48) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL5096405 | 0.74 | CTSK (0.35) | — | |
| SCHEMBL5096693 | 0.74 | PSEN1 (0.33) | — | |
| SCHEMBL7564716 | 0.73 | PSEN1 (0.34) | GHSRSLC6A2SLC6A4SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | GHSR 1254/4885SLC6A2 4474/4885SLC6A4 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.